Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Veracyte, Inc. (NASDAQ:VCYT)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Veracyte, Inc. (NASDAQ:VCYT). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Veracyte stock on March 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Veracyte Stock Down 3.2%

Veracyte stock traded down $1.06 during trading hours on Thursday, reaching $31.61. 170,105 shares of the company’s stock were exchanged, compared to its average volume of 895,221. The firm’s 50 day simple moving average is $34.48 and its 200 day simple moving average is $38.30. Veracyte, Inc. has a twelve month low of $22.61 and a twelve month high of $50.71. The firm has a market capitalization of $2.51 billion, a PE ratio of 38.08 and a beta of 1.96.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.12. Veracyte had a return on equity of 8.05% and a net margin of 12.83%.The company had revenue of $140.64 million for the quarter, compared to the consensus estimate of $135.79 million. During the same period in the previous year, the business earned $0.06 EPS. The firm’s revenue was up 18.5% compared to the same quarter last year. Analysts anticipate that Veracyte, Inc. will post 0.68 EPS for the current year.

Analyst Ratings Changes

VCYT has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Veracyte in a research note on Friday, March 27th. UBS Group reaffirmed a “buy” rating on shares of Veracyte in a research report on Monday, January 12th. Needham & Company LLC reiterated a “buy” rating and set a $48.00 target price on shares of Veracyte in a research report on Wednesday, April 1st. Guggenheim cut their target price on shares of Veracyte from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Finally, Morgan Stanley reduced their price target on shares of Veracyte from $48.00 to $37.00 and set an “underweight” rating for the company in a report on Thursday, March 5th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Veracyte has a consensus rating of “Hold” and a consensus target price of $44.20.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its holdings in shares of Veracyte by 23.3% during the first quarter. Royal Bank of Canada now owns 28,712 shares of the biotechnology company’s stock valued at $852,000 after acquiring an additional 5,435 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Veracyte by 12.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 195,793 shares of the biotechnology company’s stock worth $5,805,000 after purchasing an additional 21,330 shares in the last quarter. Jane Street Group LLC grew its position in Veracyte by 94.7% in the 1st quarter. Jane Street Group LLC now owns 216,909 shares of the biotechnology company’s stock valued at $6,431,000 after purchasing an additional 105,499 shares during the period. Intech Investment Management LLC increased its stake in Veracyte by 54.1% during the 1st quarter. Intech Investment Management LLC now owns 42,762 shares of the biotechnology company’s stock valued at $1,268,000 after purchasing an additional 15,017 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Veracyte by 259.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 336,978 shares of the biotechnology company’s stock valued at $9,109,000 after purchasing an additional 243,111 shares in the last quarter.

Insider Buying and Selling at Veracyte

In other Veracyte news, CFO Rebecca Chambers sold 18,341 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $36.14, for a total value of $662,843.74. Following the transaction, the chief financial officer directly owned 131,196 shares of the company’s stock, valued at approximately $4,741,423.44. This trade represents a 12.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John Leite sold 5,260 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $35.19, for a total transaction of $185,099.40. Following the sale, the insider directly owned 107,580 shares of the company’s stock, valued at approximately $3,785,740.20. The trade was a 4.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 75,782 shares of company stock worth $2,722,097. Corporate insiders own 1.40% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Veracyte

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.